TCGA-AR-A1AI-01A-11R-A12P-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 110
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.590
- G2M_CHECKPOINT+0.560
- MYC_TARGETS_V1+0.520
- MYC_TARGETS_V2+0.510
- INTERFERON_GAMMA_RESPONSE+0.490
- ALLOGRAFT_REJECTION+0.480
- MITOTIC_SPINDLE+0.470
- INTERFERON_ALPHA_RESPONSE+0.430
- UNFOLDED_PROTEIN_RESPONSE+0.360
- MTORC1_SIGNALING+0.350
Top 10 suppressed
- MYOGENESIS-0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.340
- ANGIOGENESIS-0.310
- COAGULATION-0.300
- ESTROGEN_RESPONSE_LATE-0.300
- ESTROGEN_RESPONSE_EARLY-0.290
- TGF_BETA_SIGNALING-0.240
- UV_RESPONSE_DN-0.230
- PANCREAS_BETA_CELLS-0.200
- BILE_ACID_METABOLISM-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 20130015.TNBC | — | E | 0.897 |
| 2 | TCGA-C8-A27B-01A-11R-A169-07 | — | E | 0.893 |
| 3 | TCGA-B6-A0X1-01A-11R-A109-07 | — | E | 0.892 |
| 4 | TCGA-AO-A0J6-01A-11R-A034-07 | — | E | 0.884 |
| 5 | 20100125.TNBC | — | E | 0.883 |
| 6 | SRR1313135 | — | C | 0.877 |
| 7 | TCGA-E2-A1II-01A-11R-A144-07 | — | E | 0.875 |
| 8 | TCGA-BH-A1FC-01A-11R-A13Q-07 | — | E | 0.872 |
| 9 | e8381a92.5379.4ece.8414.230d0f0026e1 | — | cohortA1 | 0.869 |
| 10 | TCGA-E2-A14N-01A-31R-A137-07 | — | E | 0.864 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.590 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.560 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.520 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.510 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.490 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.480 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.470 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.430 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.360 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.350 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.340 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| COMPLEMENT | 0.260 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.250 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.220 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.180 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.170 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.170 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.140 | Inavolisib | — uncovered |